Elevated staff cost post Gavis acquisition and higher than expected R&D expenses (13.3% of sales) led to a surprise sequential drop in margins at 25.0% in 2QFY17. As a result, net profits declined 15%YoY to Rs 6.6bn, despite lower taxes during the quarter. On the flip side, revenue performance was buoyant with robust US sales.